Key result
Inhibition of coagulation factors or protease-activated receptors ameliorates inflammation and kidney injury in eNOS-deficient diabetic mouse models.
Why the study?
To summarize the relationship between eNOS, coagulation, and PARs and propose a novel therapeutic option for the management of patients with DKD.
Inhibition of coagulation factors or PARs may represent a novel therapeutic option for managing inflammation in diabetic kidney disease, based on evidence from eNOS-deficient mice.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for coagulation inhibition in diabetic kidney disease; should not yet change clinical practice.
Oe et al. (2021) conducted a review in Diabetic Kidney Disease. Coagulation factor and PAR inhibition was evaluated. Inhibition of coagulation factors or protease-activated receptors ameliorates inflammation and kidney injury in eNOS-deficient diabetic mouse models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: